About us

Our History

Mission & Vision

Mission

We are committed to the success of our partners in the Pharma industry by offering tailor made solutions and leading edge expertise with a human touch to make our common growth dreams come true.
We are committed to the success of our partners in the Pharma industry by offering tailor made solutions and leading edge expertise with a human touch to make our common growth dreams come true.
To be the preferred business partner for every pharma company in the industry by leading a new generation of services in the world of generics.
To be the preferred business partner for every pharma company in the industry by leading a new generation of services in the world of generics.

Vision
Farmaprojects,
member of Polpharma B.V. group

With over 3 decades of experience in out-licensing model and regulatory affairs, Farmaprojects, as a Polpharma group member, provide full service to their business partners. Farmaprojects B2B pharma expertise round off with Polpharma’s solid manufacturing, product development and commercialization expertise. Our deep B2B knowledge, allows us to focus on delivering first class out-licensing services and reliable supply to all our clients, with a human touch.



We offer

- Attractive portfolio
- Customer centric approach
- Sustained production strategy
- Market driven
- Customized commercial conditions


Focus on the newest Cardiology trends, developing mono & combo products

Wide Oral Antidiabetics portfolio (Combinations & Plain)

Anti-obesity main Molecule (Orlistat)

Other key therapeutic groups: Antithrombotic, Nervous System and Respiratory drugs, among others

Lyophilized portfolio
Multidisciplinary Team Support



Combined efforts with Polpharma’s volumes, guarantees supply continuity

Technical team fully dedicated to secure on-time launches

2 API suppliers to reduce risks

Planning & Production Team


Dossier adjustment to different non-EU market requirements

Products tested for Zone IV territories

Flexibility of Business Model for selected markets

Early launch possibility (FTO)


Competitive COGS based on economyof scales

API manufactured internally

Dedicated Customer Service


Focus on the newest Cardiology trends, developing mono & combo products

Wide Oral Antidiabetics portfolio (Combinations & Plain)

Anti-obesity main Molecule (Orlistat)

Other key therapeutic groups: Antithrombotic, Nervous System and Respiratory drugs, among others

Lyophilized portfolio
Multidisciplinary Team Support



Combined efforts with Polpharma’s volumes, guarantees supply continuity

Technical team fully dedicated to secure on-time launches

2 API suppliers to reduce risks

Planning & Production Team


Dossier adjustment to different non-EU market requirements

Products tested for Zone IV territories

Flexibility of Business Model for selected markets

Early launch possibility (FTO)


Competitive COGS based on economyof scales

API manufactured internally

Dedicated Customer Service
Our presence in the world

Farmaprojects has a global approach, for which we are constantly working to expand our business to other markets, adapting to the uniqueness of each territory.

